Gillian C. Bethune

Halifax, NS, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Practical solutions for complex surgical problems: right operation, right place, right time: General Surgery Atlantic Conference 2026, May 22-24, 2026, Fox Harb'r Resort, Fox Harbour, Nova Scotia.

Practical solutions for complex surgical problems: right operation, right place, right time: General Surgery Atlantic Conference 2026, May 22-24, 2026, Fox Harb'r Resort, Fox Harbour, Nova Scotia.

Journal: Canadian journal of surgery. Journal canadien de chirurgie

Published: June 09, 2026

Pathological assessment of tumour beds in breast excisions post-neoadjuvant therapy: a retrospective cohort study.

Pathological assessment of tumour beds in breast excisions post-neoadjuvant therapy: a retrospective cohort study.

Journal: Histopathology

Published: January 19, 2026

THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer.

THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer.

Journal: Biomarker research

Published: July 18, 2025

Extensive Intraductal Component (EIC) as the Most Predictive Factor for Residual Disease Post-Breast-Conserving Surgery With Close DCIS Margins: A Single Institutional Experience.

Extensive Intraductal Component (EIC) as the Most Predictive Factor for Residual Disease Post-Breast-Conserving Surgery With Close DCIS Margins: A Single Institutional Experience.

Journal: International journal of breast cancer

Published: June 17, 2025

Expression of carcinoma ecotypes in the tumor microenvironment predicts response to neoadjuvant therapy in early-stage breast cancer.

Expression of carcinoma ecotypes in the tumor microenvironment predicts response to neoadjuvant therapy in early-stage breast cancer.

Journal: Scientific reports

Published: May 20, 2025

LINC01929 mediates breast cancer immunosuppression and is an immunotherapy target.

LINC01929 mediates breast cancer immunosuppression and is an immunotherapy target.

Journal: iScience

Published: March 12, 2025

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.

Journal: Breast (Edinburgh, Scotland)

Published: December 14, 2023

ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway.

ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway.

Journal: Molecular oncology

Published: April 20, 2023

Using Deep Learning to Predict Final HER2 Status in Invasive Breast Cancers That are Equivocal (2+) by Immunohistochemistry.

Using Deep Learning to Predict Final HER2 Status in Invasive Breast Cancers That are Equivocal (2+) by Immunohistochemistry.

Journal: Applied immunohistochemistry & molecular morphology : AIMM

Published: April 05, 2022

HER2 testing in metastatic breast cancer - Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?

HER2 testing in metastatic breast cancer - Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?

Journal: Annals of diagnostic pathology

Published: March 22, 2022

Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.

Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.

Journal: Breast cancer research and treatment

Published: September 17, 2020

Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry.

Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry.

Journal: Virchows Archiv : an international journal of pathology

Published: September 15, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026